The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
Open accessAbstract
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ damage. Based on 2 prospective studies in mostly adults and retrospective data in children, eculizumab, a terminal complement inhibitor, is approved for aHUS treatment. Here we prospectively evaluated efficacy and safety of weight-based dosing of eculizumab in eligible pediatric patients with aHUS in an open-label phase II study. The primary end point was complete TMA response by 26 weeks. Twenty-two patients (aged 5 months-17 years) were treated; 16 were newly diagnosed, 12 had no prior plasma exchange/infusion during current TMA symptomatology, 11 received baseline dialysis and 2 had prior renal transplants. By week 26, 14 achieved a complete TMA response, 18 achieved hematologic normalization, and 16 had 25% or better improvement in serum creatinine. Plasma exchange/infusion was discontinued in all, and 9 of the 11 patients who required dialysis at baseline discontinued, whereas none initiated new dialysis. Eculizumab was well tolerated; no deaths or meningococcal infections occurred. Bone marrow failure, wrist fracture, and acute respiratory failure were reported as unrelated severe adverse events. Thus, our findings establish the efficacy and safety of eculizumab for pediatric patients with aHUS and are consistent with proposed immediate eculizumab initiation following diagnosis in children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Equations to Estimate GFR in Children with CKD
Schwartz, G. J., Mun[Combining Tilde]oz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008030287 · Cited by 3,777
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Self-citationAtypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732
Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaimé, F., Dragon-Durey, M.-A., Ngo, S., Moulin, B., Servais, A., Provot, F., Rostaing, L., et al. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04760512 · Cited by 714
International, F. H., Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., et al. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3076-8 · Cited by 596
Self-citationThrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome
Delvaeye, M., Noris, M., De Vriese, A., Esmon, C. T., Esmon, N. L., Ferrell, G., Del-Favero, J., Plaisance, S., Claes, B., Lambrechts, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810739 · Cited by 554
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome
Lemaire, M., Frémeaux-Bacchi, V., Schaefer, F., Choi, M., Tang, W. H., Le Quintrec, M., Fakhouri, F., Taque, S., Nobili, F., Martinez, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2590 · Cited by 483
Cited by
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Fakhouri, F., Zuber, J., Frémeaux-Bacchi, V., & Loirat, C. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30062-4 · Cited by 571
Kulasekararaj, A. G., Hill, A., Rottinghaus, S. T., Langemeijer, S., Wells, R., Gonzalez-Fernandez, F. A., Gaya, A., Lee, J. W., Gutierrez, E. O., Piatek, C. I., et al. (2019) · Blood · doi:10.1182/blood-2018-09-876805 · Cited by 382
Thrombotic Microangiopathy and the Kidney
Brocklebank, V., Wood, K. M., & Kavanagh, D. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00620117 · Cited by 373
Jokiranta, T. S. (2017) · Blood · doi:10.1182/blood-2016-11-709865 · Cited by 280
Metadata
- Authors
- Greenbaum, L. A., Fila, M., Ardissino, G., Al-Akash, S. I., Evans, J., Henning, P., Lieberman, K. V., Maringhini, S., Pape, L., Rees, L., van de Kar, N. C. A. J., Vande Walle, J., Ogawa, M., Bedrosian, C. L., & Licht, C.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 89
- Issue
- 3
- Pages
- 701-711
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2264090971
- Cited by
- 296
- References
- 29
- FWCI
- 19.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. https://app.cochat.ai/papers/10.1016/j.kint.2015.11.026
- The paper
- Greenbaum, L. A., Fila, M., Ardissino, G., Al-Akash, S. I., Evans, J., Henning, P., Lieberman, K. V., Maringhini, S., Pape, L., Rees, L., van de Kar, N. C. A. J., Vande Walle, J., Ogawa, M., Bedrosian, C. L., & Licht, C. (2016). Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney International. https://doi.org/10.1016/j.kint.2015.11.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.